News

A team of researchers at Arizona State University has developed tools to aid in the diagnosis of myopic maculopathy.

Changes associated with Alzheimer's disease extend beyond the brain.

Lotfi Merabet, OD, PhD, MPH, discusses his role as co-chairman of a National Eye Institute initiative focused on advancing research in cerebral visual impairment (CVI). The initiative's key goals include raising awareness about CVI, establishing clear diagnostic criteria, and developing a national registry to track patients and their conditions over time. CVI, a complex condition that affects how the brain processes visual information, requires a multidisciplinary approach involving not only ophthalmologists and optometrists but also neuroscientists, educators, and rehabilitation specialists.

Coordinated by the International Agency for the Prevention of Blindness under the Love Your Eyes campaign banner, World Sight Day 2024 is putting children front and center in this year’s campaign.

Making the most of AI means letting go of fear, says Editorial Advisory Board member Johan Blanckaert, MD

Jeff Todd, president and CEO of Prevent Blindness, and Donna Fishman, Director of the National Center for Children’s Vision and Eye Health at Prevent Blindness, join David Hutton of Ophthalmology Times to discuss the report.

The investigators undertook a study in which they retrospectively evaluated the presence and amount of small HRF in the eyes of patients with different macular atrophic phenotypes.

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities.

Investigators studied global-flash multifocal electroretinogram responses

The donation will support the development of the Artificial Intelligence Innovation Center, a collaborative hub with a focus of preserving the vision of patients with various eye conditions and eliminating blindness.

The resubmission comes after receiving a Complete Response Letter at the end of 2023.

Marketed as Triesence, it is a preservative free synthetic corticosteroid that is approved by the FDA for visualization during vitrectomy and for the treatment of ocular inflammatory conditions that are unresponsive to topical corticosteroids.

The award from the National Institutes of Health will enable a team of researchers to investigate Alzheimer and Parkinson progression through the eye.

A different approach better serves patients with diabetic retinopathy

Ciclosporin 0.1% eye drops solution will be marketed under the brand name Vevizye in the EU for the treatment of dry eye disease.

Current and future options for Fuchs endothelial corneal dystrophy

Gene therapy was a major topic at the 2024 EURETINA and Retina Society meetings

Because the inner retinal function is thought to affect the emmetropization process, authors suggested that caffeine may be involved in ocular growth

The company’s flagship product is Reti-CVD, an AI diagnostic solution that autonomously assesses future cardiovascular disease risk using a retina scan.

The e-poster came in 2nd place for the August Deutman award at the EURETINA Congress

The TECNIS Odyssey IOL is a new full vision range IOL built on the TECNIS platform.

Ali Erginay, MD, spoke about the important developments in retinal imaging, specifically the Red-Blue-Green (RGB) imaging modalities during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Dr Yorston delivered the Gisbert Richard Lecture at this year's EURETINA Congress

The retina space continues to see new advancements and clinical trial results, many of which are shared at industry conferences throughout the year.

David Eichenbaum, MD, spoke with Modern Retina to provide and overview on his presentation at ASRS 2024 and the current state of geographic atrophy treatment.